Antipsychotic News and Research RSS Feed - Antipsychotic News and Research

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus. [More]
Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine's primary metabolite supports learning and memory by amplifying the action of a primary chemical messenger involved in both, researchers report. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Endogenous cannabinoids linked to weight gain in people with schizophrenia

Endogenous cannabinoids linked to weight gain in people with schizophrenia

Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal. [More]
Researchers identify a common pattern across different psychiatric disorders

Researchers identify a common pattern across different psychiatric disorders

In a study analyzing whole-brain images from nearly 16,000 people, researchers at the Stanford University School of Medicine identified a common pattern across a spectrum of psychiatric disorders that are widely perceived to be quite distinct. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss. [More]
Some medicines can make skin sun-sensitive, says NPS MedicineWise clinical adviser

Some medicines can make skin sun-sensitive, says NPS MedicineWise clinical adviser

Some medicines can make your skin more sensitive to the sun and this summer season NPS MedicineWise advises Australians to check their medicines packaging for warnings to avoid excessive skin exposure to sunlight and sunlamps. [More]
Longitudinal course of schizophrenia negative symptoms revealed

Longitudinal course of schizophrenia negative symptoms revealed

Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]

Antipsychotic polypharmacy prevalent despite efficacy doubts

Results of a retrospective study suggest that around a quarter of patients with schizophrenia receive antipsychotic polypharmacy, despite a lack of evidence for the approach. [More]
Novel drug target could lead to better antipsychotic medications

Novel drug target could lead to better antipsychotic medications

Scientists at the Centre for Addiction and Mental Health have identified a novel drug target that could lead to the development of better antipsychotic medications. [More]
Excess mortality in schizophrenia ‘not attributable to antipsychotics’

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found. [More]
People with first-episode psychosis may benefit from medication treatment changes, study finds

People with first-episode psychosis may benefit from medication treatment changes, study finds

Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found. Current guidelines emphasize low doses of antipsychotic drugs and strategies for minimizing the side effects that might contribute to patients stopping their medication. [More]
Lewy body dementia: 10 things people need to know

Lewy body dementia: 10 things people need to know

The recent news that the brain of actor/comedian Robin Williams showed signs of diffuse Lewy body disease has created more interest and coverage in this widely under-diagnosed condition than ever before. [More]
Successful antipsychotic treatment may alter striatal connectivity

Successful antipsychotic treatment may alter striatal connectivity

Connectivity within the striatum changes as psychotic symptoms improve in patients treated with second-generation antipsychotics, a study shows. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]

Schizophrenia symptom severity predicts atypical antipsychotic benefit

Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry. [More]
Metabolic syndrome screening in bipolar disorder warranted

Metabolic syndrome screening in bipolar disorder warranted

The frequency of the metabolic syndrome in patients with bipolar disorder warrants systematic screening, say researchers, particularly among men, older patients and those receiving atypical antipsychotic treatment. [More]